Back to News
Market Impact: 0.3
Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Pharming Group reported positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies associated with altered PI3Kδ signaling. The brief report provides no efficacy or safety figures, so the magnitude of the results cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PHAR0.65
More News
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Netwealth stock sliding today?
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment
- Bending Spoons Stock Soars on Berkshire’s Increased Stake